NCT01070186撤回2 期
Phase II, Open Label, Single Center Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 主要终点
- Time to clinical recurrence after surgery for high risk localized disease.
研究概览
简要总结
This study is designed to explore the molecular modulatory effect of Sunitinib when given in a neoadjuvant setting prior to radical or partial nephrectomy. The study will evaluate aforementioned outcomes in 30 patients at a dose of 50mg/day for 4 weeks followed by surgery 2-4 weeks following the last dose.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must be at least 18 years of age
- •Must be eligible to undergo a radical or partial nephrectomy
- •Clinical stage T1b, T2, T3, T4 and/or N1 disease as documented by abdomen/pelvis CT scan, or MRI and chest x-ray or CT chest
- •Patients must have a performance status on the ECOG scale of 0-1
- •Patients must have a pretreatment wbc > 3.0, granulocyte count > 1000/mm3, hemoglobin > 8.5 g/dL, platelet count > 100,000/mm3 and a normal PT and PTT
- •Patients must have a serum creatinine < 2.0 mg/dL
- •Patients must have adequate hepatic function with a serum bilirubin < upper limit of normal and AST/ALT < 2.5 x upper limit of normal
排除标准
- •Radiographic evidence of metastatic disease
- •Prior administration of immunotherapy/biotherapy/hormonal or radiation for renal cell carcinoma
- •Active secondary malignancies (other than basal cell carcinoma of the skin)
- •Serious, nonhealing wound, ulcer, or bone fracture
- •Clinically significant cardiovascular disease, New York Heart Association Grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication or Grade II or greater peripheral vascular disease within 1 year preceding Day 0
- •Any history or radiologic evidence of central nervous system disease
- •Active infection requiring parenteral antibiotics at the time of the first Sunitinib administration
- •Current or recent (within the 10 days preceding Day 0) use of oral or parenteral anticoagulants (except as required to maintain patency of preexisting, permanency indwelling IV catheters), or aspirin
- •Current, recent (within the 4 weeks preceding Day 0), or planned participation in another experimental drug study
- •Screening clinical laboratory values:
- •ANC of < 1000/uL
- •Platelet count of < 100,000/uL
- •Total bilirubin > 2.0 mg/dL
- •AST or ALT > 2.5 times the upper limit of normal
- •Serum creatinine of > 2.0 mg/dL
- •Hemoglobin of < 9 gm/dL (may be transfused to maintain or exceed this level)
- •Ongoing cardiac dysrhythmias of NCI CTCAE Version 3.0 grade > 2
- •Prolonged QTc interval on baseline EKG
- •Uncontrolled hypertension (>150/100 mm Hg despite optimal medical therapy)
- •Pre-existing thyroid abnormality with thyroid function that cannot be maintained in the normal range with medication
- •Patients receiving CYP3A4 inducers or inhibitors; patients should not take grapefruit juice or St. John's Wort while on the study
- •History of psychiatric disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the results of the study or render the subject at high risk from treatment complications
- •Unable to take medication by mouth
研究组 & 干预措施
Treatment
Experimental
See intervention descriptions
干预措施: Biomarkers (Other)
Treatment
Experimental
See intervention descriptions
干预措施: Sunitinib (Drug)
Treatment
Experimental
See intervention descriptions
干预措施: Tumor biopsy (Other)
Treatment
Experimental
See intervention descriptions
干预措施: Nephrectomy (Procedure)
结局指标
主要结局
Time to clinical recurrence after surgery for high risk localized disease.
时间窗: 1 year
次要结局
- Toxicity of Sunitinib when administered as neoadjuvant therapy prior to surgery(1 year)
- Effect of Sunitinib on pretreatment serum levels of Vascular Endothelial Growth Factor (VEGF). Tissue levels (biopsy and pathological specimen) of total VEGF, HIF-alpha, microvessel density, and apoptotic indices (TUNNEL Staining)(1 year)
- Radiographically quantifiable evaluation of changes in cellular disorganization (marker of necrosis) and perfusion parameters before and during the administration of Sunitinib.(1 year)
研究者
相似试验
进行中（未招募）
不适用
Etude de phase II du sunitinib ( SUTENT®) pour le traitement de patients atteints de cancer de la prostate hormono-résistant après progression sous docétaxel. - PROSUTEUCTR2007-003048-31-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
进行中（未招募）
2 期
Sunitinib Malate With Hormonal Ablation for Patients Who Will Have ProstatectomyProstate CancerNCT00329043M.D. Anderson Cancer Center64
进行中（未招募）
1 期
A phase II study looking at sunitinib treatment in patients with Renal Cell Cancer that has spread to other areas of the body.Metastatic Renal Cell CarcinomaMedDRA version: 14.1 Level: PT Classification code 10050513 Term: Metastatic renal cell carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2005-004502-82-GBCambridge University Hospitals NHS Foundation Trust and University of Cambridge16
进行中（未招募）
1 期
Phase II study of sunitinib malate (SUTENT®) in relapsed germ cell tumors in males.germ cell tumorEUCTR2007-004981-42-SKarodny onkologicky ustav28
进行中（未招募）
不适用
Study of Sunitinib in Young Patients With Refractory Solid TumoursEUCTR2012-000690-23-Outside-EU/EEAational Institution of Health (NCI)60